nach oben

Wiener klinische Wochenschrift

Erschienen in:

01.12.2016 | original article

Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2016

Einloggen, um Zugang zu erhalten

Summary

Background

Changes in high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels have been linked to residual cardiovascular risk, whereas non-HDL-C levels have been shown to be more predictive of cardiovascular risk than are low-density lipoprotein cholesterol (LDL-C) levels. We aimed to investigate the impact of HDL-C, TG, and non-HDL-C levels on acute coronary syndrome (ACS) risk with on-target LDL-C levels.

Methods

In all, 424 Caucasian patients aged over 50 years who had LDL-C levels below 3.4 mmol/l with a first or subsequent ACS event were enrolled in a multicenter, retrospective study. Lipid samples were collected within 4 days after the cardiovascular event. The subjects of the age-matched, gender-balanced control group (n = 443) had LDL-C levels below 3.4 mmol/l and were free of cardiovascular diseases.

Results

Patients with ACS had significantly higher TG and lower HDL-C levels compared with the control patients; however, we did not find any significant difference regarding non-HDL-C levels between the two groups. In regression analysis, the risk of coronary heart disease increased significantly with 1 standard deviation (SD) increase in TG and 1 SD decrease in HDL-C levels.

Conclusion

High TG and low HDL-C levels may contribute to residual cardiovascular risk in patients with well-controlled LDL-C levels; however, non-HDL-C levels at admission did not seem to be predictive for patients with ACS. Detection and treatment of secondary lipid targets such as high TG and low HDL-C levels may be important for the prevention of cardiovascular diseases.

Vorheriger Artikel Editorial

Nächster Artikel Pulse contour cardiac output monitoring in acute heart failure patients

Reiner Z, Catapano AL, De Backer G, European Association for Cardiovascular Prevention & Rehabilitation, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.CrossRefPubMed

Baigent C, Keech A, Kearney PM, Cholesterol Treatment Trialists’ (CTT) Collaborators, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.CrossRefPubMed

Kearney PM, Blackwell L, Collins R, Cholesterol Treatment Trialists’ (CTT) Collaborators, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.CrossRefPubMed

Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145:520–30.CrossRefPubMed

Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992;70:733–7.CrossRefPubMed

Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.CrossRefPubMed

Ji MS, Jeong MH, Ahn YK, et al. Impact of low level of high-density lipoprotein-cholesterol sampled in overnight fasting state on the clinical outcomes in patients with acute myocardial infarction (difference between ST-segment and non-ST-segment-elevation myocardial infarction). J Cardiol. 2014;65(1):63–70.CrossRefPubMed

Welty FK. How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? Curr Cardiol Rep. 2013;15:400.CrossRefPubMedPubMedCentral

Fukuda S, Shimada K, Fujita M, et al. Changes in serum cholesterol levels determine future risk of cardiovascular events in patients with acute coronary syndrome in the Japanese Coronary Artery Disease (JCAD) Study. J Cardiol. 2013;61:387–92.CrossRefPubMed

10.

Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002;105:1424–8.CrossRefPubMed

11.

Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.CrossRefPubMed

12.

Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective american studies. Circulation. 1989;79:8–15.CrossRefPubMed

13.

Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;115:450–8.CrossRefPubMed

14.

Ginsberg HN, Bonds DE, Lovato LC, et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:56i–67i.CrossRefPubMed

15.

Brown BG, Boden WE, Probstfield JR, AIM-HIGH Investigators, et al. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici. Am Heart J. 2011;161:538–43.CrossRef

16.

Haynes R, Jiang L, Hopewell JC, et al. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–91.CrossRefPubMedCentral

17.

Stauffer ME, Weisenfluh L, Morrison A. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. Vasc Health Risk Manag. 2013;9:671–80.CrossRefPubMedPubMedCentral

18.

Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757–63.CrossRefPubMedPubMedCentral

19.

Orakzai SH, Nasir K, Blaha M, Blumenthal RS, Raggi P. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis. 2009;202:289–95.CrossRefPubMed

20.

Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98:1363–8.CrossRefPubMed

21.

Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–9.CrossRefPubMed

22.

Cohen M, Diez JE, Levine GN, et al. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III. J Invasive Cardiol. 2007;19:525–38.PubMed

23.

Gotto AM, Moon JE. Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol. 2013;10:560–70.CrossRefPubMed

24.

Pintó X, Millán J, Muñoz A, et al. A very high prevalence of low HDL cholesterol in Spanish patients with acute coronary syndromes. Clin Cardiol. 2010;33:418–23.CrossRefPubMed

25.

Seo SM, Choo EH, Koh YS, et al. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart. 2011;97:1943–50.CrossRefPubMedPubMedCentral

26.

Schwartz GG. High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome. Am J Cardiol. 2009;104:46E–51E.CrossRefPubMed

27.

Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005;26:890–6.CrossRefPubMed

28.

Felix-Getzik EM, Kuvin JT, Karas RH. Nonoptimal high-density lipoprotein cholesterol levels are highly prevalent in patients presenting with acute coronary syndromes and well-controlled low-density lipoprotein cholesterol levels. J Clin Lipidol. 2010;4:265–71.CrossRefPubMed

29.

Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.CrossRefPubMed

30.

Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:1086–93.CrossRefPubMed

31.

Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008;51:1440–5.CrossRefPubMed

32.

Khawaja OA, Hatahet H, Cavalcante J, Khanal S, Al-Mallah MH. Low admission triglyceride and mortality in acute coronary syndrome patients. Cardiol J. 2011;18:297–303.PubMed

33.

Henkin Y, Crystal E, Goldberg Y, et al. Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. Am J Cardiol. 2002;89:7–11.CrossRefPubMed

34.

Manfrini O, Pizzi C, Trerè D, Fontana F, Bugiardini R. Parasympathetic failure and risk of subsequent coronary events in unstable angina and non-ST-segment elevation myocardial infarction. Eur Heart J. 2003;24:1560–6.CrossRefPubMed

35.

Klingenspor M, Ebbinghaus C, Hülshorst G, et al. Multiple regulatory steps are involved in the control of lipoprotein lipase activity in brown adipose tissue. J Lipid Res. 1996;37:1685–95.PubMed

36.

Pecquery R, Leneveu MC, Giudicelli Y. In vivo desensitization of the beta, but not the alpha 2‑adrenoreceptor-coupled-adenylate cyclase system in hamster white adipocytes after administration of epinephrine. Endocrinology. 1984;114:1576–83.CrossRefPubMed

37.

Yamauchi T, Iwai M, Kobayashi N, Shimazu T. Noradrenaline and ATP decrease the secretion of triglyceride and apoprotein B from perfused rat liver. Pflugers Arch. 1998;435:368–74.CrossRefPubMed

38.

Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305–11.CrossRefPubMed

39.

Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15:2073–84.CrossRefPubMed

Titel: Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome
Publikationsdatum: 01.12.2016
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 23-24/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-016-1035-4

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 23-24/2016

Ass. Prof. Dr. Andreas Hanslik ist Researcher of the Month Dezember 2016

Veranstaltungen

Elisabeth Maritschnegg, PhD, MSc, ist Researcher of the Month Dezember 2016

Perioperative erythropoietin protects the CNS against ischemic lesions in patients after open heart surgery

Genetic testing of familial hypercholesterolemia in a real clinical setting

Adult patent ductus arteriosus